Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
- US Business Made or Broke FY2021 Earnings of Big 3 Generic Makers; Nichi-Iko, Sawai Suffer Losses
May 24, 2022
- Healios Continues to Seek MultiStem Approval despite Trial Miss: CEO
May 24, 2022
- Tohoku Univ., Drug Makers, MICIN to Jointly Collect Lifestyle Data with Wearable
May 24, 2022
- OrphanPacific Grabs Japan Rights to Immedica Drug for Urea Cycle Disorder
May 24, 2022
- Shionogi President Teshirogi to Also Become Chairman from July
May 24, 2022
- First Wipe Drug for Axillary Hyperhidrosis Now Available in Japan
May 24, 2022
- Healios’ Sakigake Cell Therapy Misses Goal in Ischemic Stroke
May 23, 2022
- US Court Dismisses Astellas Claim over Lexiscan Patent
May 23, 2022
- Movicol High-Dose Version Launched for Constipation: EA Pharma
May 23, 2022
- Fostering Biopharma Startups Is Vital to New Drug Development in Japan: IQVIA
May 20, 2022
- Opdivo Expands Indication in Taiwan for RCC in Combo with Cabozantinib
May 20, 2022
- A Few More Years before Human Trials Can Start for Potential Diabetes Cure, Novo CSO Says
May 20, 2022
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- Sosei, Kallyope Partner in R&D of GPCR Targets for GI Drug Discovery
May 18, 2022
- Argenx CEO Sees Big Potential for Vyvgart with 100-Plus Diseases Driven by IgGs; Analysts Peg Peak Sales at US$5-10 Billion
May 18, 2022
- AstraZeneca Ranks Third in Japan Sales Ranking with 12.1% Growth, Good Start in Q1 Too
May 18, 2022
- 8 Japan Drug Majors’ Combined Sales Rise 10.2% in FY2021 on Global Brands, Strong Offshore Presence Is Key to Further Growth
May 17, 2022
- Minomycin Stockout Looms in Mid-June over Manufacturing Delays: Pfizer
May 17, 2022
- Shionogi Grabs Europe and Asia Rights to F2G’s Antifungal Drug
May 17, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…